Methodological issues in clinical trials of drug and behavior therapies

被引:15
|
作者
Holroyd, KA [1 ]
Powers, SW
Andrasik, F
机构
[1] Ohio Univ, Dept Psychol, Athens, OH 45701 USA
[2] Cincinnati Childrens Hosp, Div Psychol, Cincinnati, OH USA
[3] Univ W Florida, Inst Human & Machine Cognit, Pensacola, FL 32514 USA
来源
HEADACHE | 2005年 / 45卷 / 05期
关键词
clinical trial; methodology; behavior therapy; drug therapy; headache;
D O I
10.1111/j.1526-4610.2005.05100.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Trials that compare drug and behavior therapies or evaluate combination therapy raise special methodological issues. This article reviews these methodological issues and, where possible, offers guidelines for addressing them. Sources of bias in the selection and recruitment of participants and in the measurement of treatment outcomes are discussed. In addition, methodological problems presented by the differing structures of behavior and drug therapy, by confounding variables, such as allegiance effects, differential expectations and preferences for drug or behavior therapy, and differential adherence with drug or behavior therapy also are reviewed. Issues in the selection of appropriate control groups are also discussed.
引用
收藏
页码:487 / 492
页数:6
相关论文
共 50 条
  • [21] Methodological Issues in Comparative Effectiveness Research: Clinical Trials
    Peduzzi, Peter
    Kyriakides, Tassos
    O'Connor, Theresa Z.
    Guarino, Peter
    Warren, Stuart R.
    Huang, Grant D.
    AMERICAN JOURNAL OF MEDICINE, 2010, 123 (12): : E8 - E15
  • [22] Review of methodological issues of clinical trials in multiple sclerosis
    Montalban, Xavier
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2011, 311 : S35 - S42
  • [23] Methodological issues associated with clinical trials in neuropathic pain
    Gilron, Ian
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (11) : 1399 - 1402
  • [24] IMPORTANT METHODOLOGICAL FLAWS IN CLINICAL DRUG TRIALS
    MALT, U
    PSYCHOPHARMACOLOGY, 1990, 100 (04) : B6 - B6
  • [25] Methodological issues associated with preclinical drug development and increased placebo effects in schizophrenia clinical trials
    Brown, Matt A.
    Bishnoi, Ram J.
    Dholakia, Sara
    Velligan, Dawn I.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2016, 9 (04) : 591 - 604
  • [26] Design Issues in Randomized Clinical Trials of Maintenance Therapies
    Freidlin, Boris
    Little, Richard F.
    Korn, Edward L.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2015, 107 (11):
  • [28] Methodological Issues in Clinical Drug Development for Essential Tremor
    Carranza, Michael A.
    Snyder, Madeline R.
    Elble, Rodger J.
    Boutzoukas, Angelique E.
    Zesiewicz, Theresa A.
    TREMOR AND OTHER HYPERKINETIC MOVEMENTS, 2012, 2
  • [29] Attrition in randomized controlled clinical trials: Methodological issues in psychopharmacology
    Leon, Andrew C.
    Mallinckrodt, Craig H.
    Chuang-Stein, Christy
    Archibald, Donald G.
    Archer, Graeme E.
    Chartier, Kevin
    BIOLOGICAL PSYCHIATRY, 2006, 59 (11) : 1001 - 1005
  • [30] Methodological Issues and Publication Bias in Reporting Clinical Trials in Schizophrenia
    Bowcut, Jana
    Levi, Linda
    Livneh, Ortal
    Davis, John M.
    Weiser, Mark
    NEUROPSYCHOPHARMACOLOGY, 2018, 43 : S342 - S342